



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Cross-linking mass spectrometry

Citation for published version:

O'Reilly, FJ & Rappsilber, J 2018, 'Cross-linking mass spectrometry: methods and applications in structural, molecular and systems biology', *Nature Structural & Molecular Biology*. <https://doi.org/10.1038/s41594-018-0147-0>

Digital Object Identifier (DOI):

[10.1038/s41594-018-0147-0](https://doi.org/10.1038/s41594-018-0147-0)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Nature Structural & Molecular Biology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1 **Cross-linking/mass spectrometry:**
2 **methods and applications to structural, molecular and systems**
3 **biology**

4 Francis J O'Reilly^{1,2} and Juri Rappsilber*^{1,2}

5 ¹Bioanalytics, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany

6 ²Wellcome Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom

7
8 **Abstract**

9 Over the last decade, cross-linking/mass spectrometry (CLMS) has developed
10 into a robust and flexible tool that provides medium-resolution structural
11 information on previously intractable protein complexes and and their
12 interactions. CLMS data describes the proximity of amino acid residues and
13 therefore information on the fold of proteins, and the topology of their complexes.
14 Here, we describe notable successes of this technique and common pipelines.
15 Novel CLMS applications such as *in-cell* cross-linking, probing conformational
16 changes and tertiary structure determination are beginning to make large
17 contributions to molecular biology and the emerging fields of structural systems
18 biology and interactomics.

19
20 **1. Introduction**

21 Cross-Linking/Mass Spectrometry (CLMS, also abbreviated as CL-MS, XL-MS,
22 CX-MS, or CXMS) has developed in recent years into a robust technology that is
23 accessible to many biochemical laboratories. It is now a standard complementary
24 tool to traditional structural techniques¹ and has benefited from intense
25 methodological development. Pioneering laboratories now focus on expanding
26 CLMS pipelines to generate even greater amounts of information on protein
27 structure, protein complex topology, quantitation of conformational states and
28 analysing protein-protein interactions (PPIs) on a system-wide scale.

29 The cross-linking reaction adds new covalent bonds between proximal
30 residues. Commonly, this is done with soluble cross-linkers that target surface
31 residues (Table 1). Alternatively, photoactivatable amino acids such as photo-
32 methionine and photo-leucine² can be globally incorporated during translation,
33 allowing the protein interior and hydrophobic patches to be probed. Distance
34 restraints are generated by identifying the cross-linked residues and considering
35 the length of the most extended conformation of the cross-linking reagent. These
36 data are then used, often in conjunction with other available structural
37 information, for modelling the conformation of proteins and the topology of their
38 complexes.

39 The experimental steps in CLMS typically involve the reaction, digestion of
40 cross-linked proteins, enrichment of the cross-linked peptides and tandem mass
41 spectrometry-based data acquisition followed by peptide identification by
42 database searching (Fig. 1). There are many different approaches to each of
43 these steps and therefore many potential ways to combine them into a pipeline³.
44 After protein digestion, normally by trypsin, cross-linked peptides are sub-
45 stoichiometric compared to their non-cross-linked linear counterparts as not
46 every protein or peptide is cross-linked in the same way. Detecting cross-linked
47 peptides within these mixtures has been the longstanding bottleneck of the
48 CLMS pipeline.

49 Improvements in cross-linking reagents, mass spectrometers and
50 database searching algorithms have resulted in the successful application of
51 CLMS to systems with increasing complexity⁴⁻⁶ and have vastly improved the
52 sensitivity of cross-link detection and/or identification⁷. Major advantages,
53 compared with other structural techniques, are that the cross-linking reaction
54 occurs in solution, it tolerates a large variety of buffer conditions, deals with
55 sample heterogeneity and requires relatively small sample quantities. CLMS
56 played a significant role in some of the most ambitious recent integrated
57 structural biology studies, including the mitochondrial ribosome⁸, the mediator-
58 RNA polymerase II complex⁹ and the mammoth task of piecing together the
59 membrane-bound nuclear pore complex¹⁰⁻¹².

60 Proteins and protein complexes are not static entities and CLMS captures the
61 ensemble of their conformations in solution, providing information on dynamics
62 and flexible regions. Quantitative CLMS (QCLMS) developments now allow for
63 direct comparison of cross-links derived from a complex in different states, i.e. in
64 the presence and absence of an effector. Differences in cross-link patterns could
65 be due to conformational differences between the two samples. This contrasts
66 with most other structural techniques, which normally require conformational
67 homogeneity of the sample. CLMS also has the unique potential to contribute to
68 the field of 'structural systems biology' by not only providing high-throughput
69 mapping of cellular PPIs *in vivo* or *in vitro*, but also adding the missing
70 information on protein conformations and interaction topologies to cellular
71 interaction networks.

72

73

74

75 **2. CLMS applications**

76 **CLMS applied to protein assemblies**

77 The most established application of CLMS is to investigate the topology of
78 enriched or purified protein complexes (Fig. 2a). Unlike for other structural
79 techniques, the sample does not need to be purified, although significant
80 enrichment of the protein complex will improve cross-link detection, and the
81 quantities required are relatively small (10's-100's µg). The combination of CLMS
82 with other structural and modelling techniques, often termed 'integrative structural
83 biology', has been used to determine the subunit/domain organisation of
84 complexes and assign ambiguous densities in EM maps to specific subunits¹³⁻¹⁵.
85 It helped identify that previous structural work on the CCT chaperonin rings had
86 placed homologous subunits in the wrong order^{16,17}. The cross-linking reaction
87 occurs in solution in near-native conditions and so is an ideal complementary
88 technique to address possible artifacts of other experimental approaches such as
89 crystal contacts perturbing protein structure.

90 Particularly fruitful recent applications of CLMS in combination with high-
91 resolution electron microscopy have provided important structural information on
92 the positions and orientations of subunits for challenging large protein
93 assemblies that had previously eluded structural determination. These structures
94 include: the 26S proteasome holocomplex structure¹⁸, the 40S ribosome-eIF1-
95 eIF3 complex¹⁹, the chromatin-remodelling complex SWR1²⁰, the INO80
96 chromatin remodeller²¹, the RNA polymerase II-TFIIF complex¹³, RNA
97 polymerase II coupled with the pre-mRNA capping complex²², RNA polymerase
98 II-mediator core initiation complex⁹, the mitochondrial ribosome⁸, the yeast
99 spliceosome²³ and the nuclear pore complex^{11,12}.

100 CLMS paired with integrative protein structural modelling has spurred the
101 development of specialised restraint-driven pipelines where the cross-links put
102 limitations on potential subunit orientations, restricting the energy landscape to
103 drive sampling in a way that will lead to accurate models^{24,25}. Further valuable
104 topological information such as stoichiometries and surface-accessible regions
105 can be integrated from other MS-based technologies such as ion mobility MS,
106 native MS²⁶ and hydrogen-deuterium exchange MS²⁷. Lower-resolution
107 structural models of complexes that are not amenable to standard structural
108 techniques can be built by combining biochemical and genetic evidence with
109 CLMS and available atomic-level information, as work on the SAGA transcription
110 coactivator complex²⁸ and the SEA complex²⁹ demonstrate.

111 CLMS cannot normally discriminate between intra-subunit and inter-
112 subunit cross-links in homomultimeric complexes except for the rare case where
113 a cross-link is identified between two peptides that overlap in sequence and

114 therefore cannot be from the same protein molecule³⁰. An elegant solution to this
115 is to mix stable isotope-labelled subunits e.g. ¹⁵N-labelled protein with unlabelled
116 ¹⁴N protein³¹. Cross-links between subunits are differentiated as linking a ¹⁵N
117 labelled peptide to a ¹⁴N peptide that has been used to analyse the oligomeric
118 state of guanylyl cyclase-activating protein 2³² and p53³³.

119 CLMS can also be used to confirm that complex topologies derived from *in*
120 *vitro* experiments correspond to those found *in situ*. In a study on the
121 SMC2/SMC4 subcomplex³⁴, the purified complex was first analysed by CLMS *in*
122 *vitro*. To validate that the identified *in vitro* topology occurs in the cell, the
123 detected cross-links were used to direct a targeted mass spectrometry approach
124 in order to find the same cross-links in *in situ* cross-linked chromatin.

125 The approaches described above rely on a combination of lower density
126 cross-links with higher resolution information about individual subunits. However,
127 such information is not always available for all subunits within a complex.
128 Furthermore, the analysed system may undergo conformational changes or
129 display a dynamic behaviour that cannot be deduced from the structures of the
130 individual subunits.

131 **CLMS for tertiary protein structure determination**

132 A truly non-specific cross-linker could provide distance restraints between
133 surface residues of any type. The potential combinations of cross-linked residues
134 obtained with such a cross-linker means that the data would be challenging to
135 analyse. A compromise is to use heterobifunctional reagents such as
136 sulfosuccinimidyl 4,4'-azipentanoate (sulfo-SDA). This cross-linker combines a
137 sulfo-NHS ester and a promiscuous UV photoactivatable diazirine group⁷. One
138 arm of this cross-linker is first anchored on a lysine, serine, threonine or tyrosine
139 and the other is free to link any residue after photoactivation, making data
140 acquisition and analysis simpler than for a truly random cross-linker. Data from
141 this type of cross-linker has been termed high-density cross-linking (HD-
142 CLMS)^{35,36}. Nevertheless, the increased sample complexity and the increased
143 search space have so far limited the application of this approach to single
144 proteins.

145 High-density information from CLMS can be leveraged to facilitate
146 generation of structural models *de novo* without any prior knowledge of the
147 protein structure (Fig. 2b). HD-CLMS derived distance restraints are combined
148 with computational approaches that predict protein folds by restraining the
149 proximity of structural domains, loops and residues. Small numbers of cross-links
150 have previously been used to validate predictions made through computational

151 approaches^{37,38}, and have proven to be largely complementary to evolutionary
152 conserved contacts³⁹. In the first study to show that it is possible to collect the
153 numbers of restraints with sulfo-SDA required to make sensible tertiary structure
154 predictions, we probed the 66 kDa human serum albumin. This study reported
155 1495 cross-links that were used in a hybrid modelling pipeline to predict the HSA
156 domains that broadly agreed with the known crystal structure⁷.

157 HD-CLMS has now been incorporated into the Critical Assessment of
158 protein Structure Prediction (CASP), a community effort to test the success of
159 algorithms for predicting structures of proteins for which the structure is known
160 but is yet to be publicly released. HD-CLMS debuted at CASP11 where the
161 inclusion of HD-CLMS restraints produced a modest improvement over other
162 molecular modelling approaches but most importantly, it provided a foundation
163 on which to design further integration of this data^{40,41}.

164 Additional complementary cross-links such as those with a shorter spacer
165 length to give tighter distance restraints, or cross-links in the core of the protein
166 by photoactivatable amino acids will provide more restraints for proteins that are
167 difficult to model. HD-CLMS may become an invaluable tool for solving novel
168 structures that have to date evaded standard structural biology techniques.

169 **Quantitative CLMS for comparative studies**

170 Generally, CLMS data has been interpreted under the assumption that the
171 investigated protein or protein complexes are static entities. However, a purified
172 protein can be an ensemble of many different states. Thus, CLMS studies often
173 produce high-confidence cross-links that cannot be explained by the available
174 crystal structures used to benchmark them. Some of these discrepancies may
175 represent conformations that are present in solution but are not available in the
176 PDB⁴². Since cross-linking data can represent a mixture of all of the
177 conformations occurring in the system, a careful analysis of long-distance cross-
178 links can be used to separate these alternative conformations. This approach has
179 led to key insights into the GRK5 interaction with the b2-adrenergic receptor⁴³.

180 The analysis of conformational changes by cross-linking is eased by
181 designing comparative analyses^{44,45} such as using isotope-labelling techniques,
182 which allow direct comparison of the abundances of specific cross-links between
183 different protein states (Fig. 2c). Early applications of this method were to
184 investigate the conformational changes that take place after spontaneous
185 hydrolysis of a thioester bond in the complement protein C3⁴⁶ and the impact of
186 phosphorylation on the conformation of an F-type ATPase, by comparing cross-
187 links derived from complexes treated with either BS3-d0 or BS3-d4⁴⁷. The

188 relative abundances of the cross-links were compared manually. Since then,
189 efforts have been made to automate this approach with XiQ⁴⁵, xTract⁴⁸ and
190 incorporation into MaxQuant⁴⁹. Other applications of this technology have shown
191 large conformational rearrangements that occur in the proteasome during particle
192 assembly⁵⁰, the regulation of enzymes^{48,51,52} and the regulation of protein
193 interactions^{53,54}.

194 QCLMS has shown the most success in cases where conformational
195 equilibria can be strongly shifted by, for example, effector binding or post-
196 translational modifications. However, even subtle structural changes that result in
197 altered residue proximities, solvent accessibility or steric hindrances have also
198 been observed to affect the formation and yield of cross-links⁵⁵. Great care
199 should be taken in interpreting cross-link changes if factors affecting cross-link
200 reactivity are changed, for example differences in pH, or factors affecting
201 digestion such as differential post-translational modification.

202 **CLMS applied to proteome-wide scales**

203 CLMS offers the possibility to generate distance restraints across the entire
204 proteome that reveal medium resolution structural information of proteins and
205 their interactions (Fig. 2d). This is extremely ambitious due to the complexity of
206 the starting material. Complexity here refers to the total proteins in the sample
207 and all possible combinations of their resulting peptides that need to be
208 considered during data analysis.

209 Cellular PPIs range from stable 'core' complexes to very transient
210 interactions. Large-scale proteomics studies that have provided the most
211 comprehensive PPI maps by affinity-purification/mass spectrometry^{56,57} or co-
212 fractionation^{58,59} do not reveal the physical arrangement of proteins within the
213 identified complexes. CLMS can add this missing topological information to the
214 PPI maps and also capture interactions that may be lost during purification. The
215 number of different proteins, the range of abundances and the post-translational
216 modifications in the cell makes the detection of cross-links for all but the most
217 abundant proteins difficult. Nevertheless, rapid technological advancements in
218 CLMS are now allowing production of PPI networks on starting material that only
219 a few years ago would have been impossibly complex.

220 In general, there are three different approaches to generating starting
221 material for CLMS-based PPI maps; targeted pull-downs, cell lysates and *in situ*
222 cross-linking.

223 Pull-down studies that enrich the native complex being investigated
224 combined with on-bead cross-linking can provide topological information that can

225 be used to separate direct binders from background⁶⁰⁻⁶². In the case of protein
226 phosphatase 2A (PP2A), pull-downs and on-bead cross-linking were used to
227 disentangle a complicated interaction network that consists of many different
228 isoforms¹⁴. Whereas particularly transient interactions are lost during these pull-
229 down protocols, there have also been promising studies using *in situ* stabilisation
230 of the tagged protein complexes by cross-linking in their native environment prior
231 to the pull-down. These studies have utilised cross-linkers that can penetrate cell
232 membranes and cross-link protein complexes in cells or in organelles. The
233 tagged proteins can be pulled-down along with their interaction network under
234 denaturing conditions, and this approach has been used most notably in the
235 proteasome interactome⁶³.

236 CLMS studies applied to the whole soluble proteome in cell lysates have
237 reported several hundreds of PPIs in several species, including human cell
238 lines^{6,64-66}. The data generated so far has been sparse and the majority of the
239 cross-links are within abundant and well-characterised complexes such as the
240 nucleosome, ribosome and proteasome. While a single confident inter-protein
241 cross-link is enough to confirm an interaction, it is preferable to get a density of
242 cross-link distance restraints that would provide topological information. One
243 possibility to navigate around this complexity is to cross-link cell lysates simplified
244 by biochemical fractionation⁶⁷.

245 Several attempts have been made to produce cross-link-based interaction
246 maps *in situ* in cells or organelles without genetic tagging or pull-downs in order
247 to preserve the important contribution of molecular crowding to *in vivo*
248 interactions, and to maintain the most physiologically relevant conditions. These
249 approaches produce the most complex starting material of all and although the
250 cross-linkers used are often chemically enrichable, here too only moderate
251 numbers of cross-links are identified^{4,68-71}. Excitingly, even with current
252 superficial insights, cross-linking intact cells has revealed interesting biology
253 including the interaction dynamics of HSP90⁷², interactions between bacterial
254 virulence factors and host proteins⁷³, and it has suggested supercomplexes in
255 the mitochondrial oxidative phosphorylation system^{4,71}. Cross-links can be used
256 to check the proposed folds of homology models of protein structures from
257 species that had not been previously structurally investigated⁶⁷.

258 Many novel interactions and previously unknown quaternary structures
259 have been identified in these *in situ* studies but often with insufficient numbers of
260 cross-links to enable modelling of the interacting surfaces or docking. Using the
261 NHS-ester cross-linker DSS, it is possible to identify in the order of 50-100 cross-
262 links on a typical purified protein, so for a human proteome cross-linking
263 experiment, a crude conservative estimate is that >200,000 cross-links are there

264 to be identified within and between the 4000 most abundant proteins. This
265 represents a significant analytical challenge and demonstrates that
266 improvements in the enrichment and analysis of cross-linked peptides are
267 required.

268

269 **3. CLMS workflows**

270 The development of standardised reagents and workflows have hugely increased
271 the ease-of-use of CLMS, though the abundance of available workflows may
272 cause confusion to newcomers. Below, we discuss the major integrated CLMS
273 workflows that are streamlined pipelines built around specific cross-linker
274 chemistries and search software. There are now numerous different software
275 solutions available for identifying cross-linked peptides⁷⁴. Regardless of the
276 search software used, the standard method to gauge confidence is FDR
277 estimation by a target-decoy approach^{30,75,76}. Reporting standards (Box 1) and
278 data visualisation software (Box 2 and Fig. 3) are easing interpretation and
279 transfer of results necessary for the democratisation of this technique.

280 Importantly, the chemistry of the cross-linker spacer (the part remaining
281 after a cross-link is formed) can be modified to aid data analysis and give
282 confidence to the identified cross-links. Therefore, the most suitable cross-linker
283 in combination with the analysis pipeline should be carefully considered before
284 embarking on a study.

285 **Universal approach**

286 This is the broadest approach that requires no modification to the cross-linker
287 spacer to aid downstream analysis. This is widely used in combination with
288 standard commercial cross-linkers and is particularly useful for cross-linkers that
289 are currently incompatible with modification of their spacer region, such as photo
290 amino acids^{2,77}. Isotope-labelling is not required for identification and can
291 consequently be used for quantitative or comparative studies (Fig. 4a).

292 This strategy takes advantage of the accuracy with which modern mass
293 spectrometers can record fragmentation spectra. The high mass accuracy limits
294 the chance of false positives by randomly matching signals to the database of
295 potential cross-linked peptides. Many software suites, including StavroX⁷⁸, Xlink-
296 Identifier⁷⁹ and Xcomb⁸⁰ generate a database of potential cross-linked pairwise
297 peptide combinations, but as the number of proteins increases, they can require
298 impractical amounts of computational time. Other approaches use an open
299 modification search strategy where each cross-linked spectrum is searched as
300 two peptides, each with a modification of an unknown mass at an unknown

301 residue/lysine⁸¹. Commonly used search strategies also combine the modification
302 search with experimental heuristics that enrich for potential cross-linked peptides
303 computationally to save search time before scoring the spectra, including Xi⁸²,
304 Plink⁶⁵, XLSearch⁸³, Protein Prospector⁸⁴, ECL2⁸⁵ and Kojak⁸⁶.

305 Xi, a search software of our design, first linearises spectra *in silico*⁸² and
306 then performs a simple linear search on that spectra, which outputs a list of
307 candidates for one of the linked peptides. The linearisation step uses an
308 empirical understanding of the fragmentation spectra of cross-linked peptides,
309 revealing cross-linked fragments due to their charge and fractional mass. Some
310 peptides do not fragment well so we do not necessarily expect to identify both
311 cross-linked peptides in this first step. For each of the candidates, the mass of
312 this first peptide and the mass of the cross-linker are known. Consequently, a
313 mass of the second peptide can be calculated (precursor mass – (cross-linker +
314 peptide 1)). Every peptide that fits this mass is considered as a candidate peptide
315 and all predicted pairs are used to score the whole spectrum. Xi identifies up to
316 ~20% more links compared to algorithms that only consider Lys-Lys linkages by
317 also searching side reactions of the amine-reactive cross-linker with serine,
318 threonine and tyrosine residues⁸⁷. Xi also permits the search for products of
319 photo-cross-linking to obtain high-density CLMS data⁷. A false discovery rate
320 (FDR) for this data can be calculated using a target-decoy approach with our
321 software xiFDR⁷⁵ that has an integrated option to further increase identifications
322 through noise reduction.

323 **Labelled cross-linker approach**

324 This approach is designed to indicate in the first mass spectrometry stage (MS1)
325 which peptides contain a cross-linker, whether those are cross-linked peptides or
326 simply cross-linker modified peptides (i.e. mono-links), and to reveal cross-linked
327 fragments (Fig. 4b). This helps to identify cross-links, which is especially
328 beneficial for confident cross-link identification in cases where high-accuracy
329 mass spectrometers are not available. It also simplifies the data analysis
330 workflow. Several labelling strategies exist⁸⁸⁻⁹⁰. The most common is to use a 1:1
331 mixture of heavy and light isotope-labelled cross-linkers during the reaction. This
332 produces a characteristic doublet in MS1 spectra that is recognised by search
333 software. Several search software take advantage of this approach including:
334 Hekate⁹¹, StavroX⁷⁸ and the popular xQuest⁹².

335 For example, xQuest identifies the linked peptides using the fragmentation
336 spectra (MS2) of both the light- and heavy-labelled MS1 precursors. Linear
337 peptide fragments, which do not contain the labelled cross-linker are common

338 peaks in both fragmentation spectra and can be used to map the two cross-
339 linked peptides⁹³ (Fig. 4b). This reduces the potential search space by generating
340 lists of candidate peptides that can then be scored against the full MS2 spectra.
341 xProphet, a software package that is paired with xQuest, then calculates FDRs
342 using a target-decoy approach⁷⁶.

343 However, this elegant approach has disadvantages. Peptides modified
344 with the isotopically heavy and normal cross-linker can differ in retention time on
345 the reverse-phase liquid chromatography in line with the mass spectrometer,
346 which can make it difficult to identify the pairs. Requiring both the heavy and light
347 precursors to be picked for fragmentation can cause issues in complex samples.
348 Labelling with a 1:1 ratio of light/heavy cross-linker causes the intensity of the
349 cross-linked peptides to be halved relative to the unlabelled linear peptides in the
350 sample. This decreases the likelihood that their precursors are selected for
351 fragmentation. Labelling also increases the complexity of the MS1 spectral space,
352 which can negatively affect identification rates. Moreover, use of labelled cross-
353 linkers to identify linked peptides prevents their use of this for QCLMS (see
354 'Quantitative CLMS for comparative studies').

355 **MS2-cleavable cross-linker approach**

356 Cross-linked peptides are large and branched, which gives rise to complicated
357 fragmentation spectra and uneven fragmentation. The large number of potential
358 peptide combinations in conjunction with the often poor fragmentation of one of
359 the cross-linked peptides can make it difficult to confidently identify the two
360 peptides. Separating the two peptides in the mass spectrometer simplifies the
361 analysis to identifying two individual linear peptides (Fig. 4c).

362 Consequently, considerable effort has been expended on creating cross-
363 linkers that are cleavable in the mass spectrometer so that spectra simply
364 correspond to two modified peptides⁹⁴⁻¹⁰⁵.

365 MS2-cleavable cross-linker approaches tend to cleave asymmetrically
366 during mass spectrometric fragmentation, which provides distinctive cross-link
367 specific product ions that report the presence of cross-linked peptides. DSSO
368 (see Table 1), for example, cleaves asymmetrically leaving a distinctive group of
369 4 peaks after CID (collision-induced dissociation) fragmentation: peptide A with
370 the longer arm of the cleaved DSSO, peptide B with the shorter arm and *vice*
371 *versa*⁹⁴ (Fig. 4c). These can be selected for further fragmentation (MS3), which
372 simplifies the spectra to that of a simple modified peptide with a measured parent
373 m/z and therefore aids identification. The use of MS3 requires an instrument that
374 is capable of doing MS3 - and this technique takes longer duty cycles than the

375 MS2-only approaches discussed above. Acquisition approaches for these cross-
376 linkers have subsequently been designed by several laboratories along with their
377 respective search software such as ICC-CLASS¹⁰⁶, MeroX¹⁰⁷, X-links/Blinks^{108,109}
378 and XlinkX2.0^{6,66}.

379 In the XlinkX pipeline, a mixed approach is recommended by performing
380 sequential CID and ETD (electron-transfer dissociation) fragmentation on each
381 precursor. Fragment ions displaying the characteristic doublets of DSSO are
382 selected for further MS3 analysis⁶⁶. The information from all three of these
383 fragmentation approaches is then combined for identification. This data
384 integration circumvents a large drawback with this approach whereby the MS2-
385 cleavage of the cross-linker is often inefficient and therefore doublet peaks are
386 not always obvious for selection for MS3.

387

388 **4. Future prospects**

389 The field of CLMS is providing powerful tools to molecular biologists to aid
390 structural biology and interactome research. CLMS has matured into a core
391 technique for *in vitro* structural studies that is capable of delivering medium
392 resolution information to complement classical atomic resolution structural
393 biology techniques and computational modelling. CLMS results from a purified
394 protein complex can be generated and analysed in under a week by most
395 proteomics core facilities. The addition of QCLMS, which may soon become
396 routine, means that structural differences caused by conformational changes or
397 mutations can be assessed in solution. HD-CLMS has demonstrated potential for
398 aiding the characterisation of tertiary protein structure in combination with
399 computational modelling.

400 *In situ* studies of PPIs and protein structures is the next phase of the
401 CLMS revolution. As work continues towards acquiring data of greater depth,
402 CLMS may eventually become a widely-used quantitative *in cell* structural
403 technique to monitor interactions and conformational changes simultaneously.
404 Several hundreds to thousands of cross-linked residue pairs can be identified
405 from purified protein complexes so the few thousands of cross-linked peptides
406 that have so far been detected in 'proteome-wide' studies are only the tip of the
407 iceberg. Improved cross-linked peptide enrichment, cross-linker chemistries, and
408 further progress in data acquisition and analysis will allow us to map many tens
409 of thousands of cross-links within the cell and elucidate protein topologies *in situ*
410 at a true proteome-wide scale. One envisions a time in the near future when
411 CLMS will be used to routinely map entire protein interactomes and their
412 dynamics during biological processes such as cellular differentiation,

413 development and the transition from health to disease.

414

415 **Acknowledgements**

416 We apologise to our colleagues for the many missing citations to their work which
417 were omitted solely to keep this introductory review lean or due to our own
418 ignorance. We would like to thank the reviewers for their very helpful
419 suggestions.

420

421 **Funding info**

422 This work was supported by the Einstein Foundation, the DFG [RA 2365/4-1],
423 and the Wellcome Trust through a Senior Research Fellowship to JR [103139].
424 The Wellcome Centre for Cell Biology is supported by core funding from the
425 Wellcome Trust [203149].

426

Cross-linker	Spacer length	Residue reactivity
BS3/DSS	11.4 Å	K/S/T/Y/N-terminus - K/S/T/Y
DSSO	10.3 Å	K/S/T/Y/N-terminus - K/S/T/Y
EDC	0 Å	D/E - K/S/T/Y
DMTMM + spacer dihydrazine	Depends on spacer	D/E - D/E
SDA	3.4 Å	K/S/T/Y/N-terminus - Any

427 **Table 1| A selection of commonly used soluble cross-linkers and their**
428 **reactivities.** *Cross-linkers comprise two elements: reactive end-groups and a*
429 *spacer. The reactive groups dictate which residues are targeted and thereby the*
430 *amount of spatial information that can be obtained. Cross-linkers that target*
431 *specific reactive groups generate fewer potential combinations of cross-linked*
432 *residues, which limits the amount of structural information but also eases the*
433 *data analysis. The spacer region of the cross-linker is what remains when two*
434 *residues are cross-linked and largely determines the workflow to be used*
435 *including the MS acquisition method and data analysis. The spacer also*

436 *influences the spatial resolution and data density. A longer spacer will allow more*
437 *residue combinations to fall within a cross-linker's range, which may be beneficial*
438 *if the main goal is to identify proteins (not necessarily the residues) that are in*
439 *close proximity. However, a longer spacer also reduces the information value of*
440 *a cross-link as a cross-link only produces an upper bound distance restraint.*
441
442

443 **Box 1: Reporting standards**

444 The field has not yet settled on minimal reporting standards. This has
445 disadvantages for assessing publications and reusing data for modelling. The
446 proteomics standards initiative (HUPO-PSI) has developed an XML-based
447 reporting standard for proteomics data, mzIdentML
448 (<http://www.psidev.info/mzidentml>), which from version 1.2 includes CLMS¹¹⁰.
449 Published mass spectrometric raw data should be deposited in
450 ProteomeXchange. When reporting results, there is a need for disambiguation
451 with regards to the term 'cross-link', which is often used without clear distinction
452 for peptide spectral matches (PSMs), peptide pairs and residue pairs. This is
453 confusing when trying to assess data quantity, as PSMs and peptide pairs
454 contain redundant information, and can lead to serious flaws in data reliability⁷⁵.
455 As a minimum, authors must define the term and use it consistently.


456

457 **Box 2: Data visualisation and interpretation**

458 Commonly, laboratories interested in applying CLMS to their structural problem
459 will collaborate with laboratories that specialise in CLMS or proteomics core
460 facilities to generate data. To facilitate the accessibility and interpretation of
461 CLMS results for experts and non-experts, software has been developed by
462 several laboratories for visualising the identified cross-links and the mass spectra
463 that led to their identification^{91,111–117}. Cross-linking studies provide many levels of
464 information; residue-residue links, 3D structural information (when integrated with
465 atomic level information) and protein-protein interactions, which has required
466 bespoke visualisations (Fig. 3).

467

468



470

471

472

473

474

475

476

477

478

479

480

481

482


483

484

485

486

Fig. 1| General CLMS workflow. **a**, Cross-linkers can contain various chemistries and lengths. Depending on the experimental workflow used (see CLMS data analysis and integrated workflows), the cross-linker spacer may need to be cleavable, labelled or have enrichable moieties. Reactive groups are also variable (Table 1). **b**, Concentrations and reaction times need to be empirically checked for each application to achieve optimal amounts of cross-linking. **c**, Proteins can be digested in solution or in gel to produce a mixture of cross-linked and linear peptides. **d**, After digestion cross-linked peptides are often enriched due to the large abundance of linear peptides for all applications more complex than a single protein. This can be achieved by chromatographic methods such as size exclusion chromatography or strong cation exchange chromatography. **e**, MS/MS pipelines have been designed to increase the likelihood of selecting cross-linked peptide precursors for fragmentation. **f**, Various search software solutions are described in the main text that can identify the two linked peptides from the spectra.



487

488

489

490

491

492

493

494

495

496


497

498

499


500

Fig. 2| CLMS applications. *a*, Distance restraints from CLMS allows docking of subunits of protein complexes. Together with other structural techniques such as cryo-EM can be used to provide medium to high resolution structural information for previously intractable complexes. *b*, High-density cross-linking using photo-activatable cross-linkers, while limited by sample complexity provides data density that can be used to guide algorithms that fold the tertiary structure of proteins using de novo or database aided approaches. *c*, QCLMS can describe structural differences between two protein/protein complex conformations by using isotope labelling to compare the abundances of cross-links detected in different samples. *d*, The complexity of samples analysed by CLMS has increased in recent years to include cell lysates and in situ analyses of organelles and whole cells. It is also possible to target specific interaction networks by cross-linking the cells and then pull-down a specific protein and its interactors.



501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520

Fig. 3| Visualisation solutions for CLMS data. *a*, Spectra identified as cross-linked peptides can be manually assessed. To aid this, spectral viewer *XiSPEC*¹¹⁸ highlights fragment peaks have been used to identify the linked peptides and their fragmentation coverage. *b*, Cross-linked proteins can be visualised using node and edge graphs to display interconnectivity of proteins. Intralinks and interlinks are visualised at residue and domain resolution by representing the proteins as bars or concatenated into circle plots, as used in *XiNet*¹¹¹ and *XVis*¹¹². Cross-linked edges can also be colored to aid interpretation of qCLMS data. *c*, Mapping of cross-links on known 3D structures or homology models can score and validate cross-links and show those that violate the distance restraints, as implemented in *xiNET*¹¹¹, *Xlink Analyzer*¹¹³, *XLink-DB*¹¹⁴, *Xwalk*¹¹⁵, *CLMSVault*¹¹⁶, *ProXL*¹¹⁷ and *Hekate*⁹¹. This same information can be visualised as a distogram - a histogram that shows the distribution of cross-link distances in the data¹¹¹. Normally a distance restraint is considered satisfied if the euclidean distance between Ca's is less than the cross-linker spacer, plus the side chains, plus an empirically derived short distance accounting for flexibility in the peptide backbone



521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544

Fig. 4| CLMS data acquisition and analysis workflows. **a**, The ‘universal approach’ uses cross-linkers with simple spacers. The fragmentation spectra are a mixture of fragments from both peptides and must be resolved during database search. **b**, The sample is cross-linked with a mixture of cross-linker and its heavy isotope labeled counterpart. Here usually all MS1 precursors are fragmented and during database searching the MS1 doublets (peaks separated by the mass difference between the cross-linkers) are used to indicate spectra that contain cross-linker. When the MS2 spectra from heavy and light labeled peptides are compared, peaks with a shifted mass (here indicated with stars) indicate fragments that contain the cross-linker and can therefore simplify data analysis. **c**, The ‘MS cleavable cross-linker approach’ can be done in one of two ways. The cross-linker is cleavable in the MS2, often asymmetrically, so it produces fragments that indicate the separate masses of the two cross-linked peptides. These MS2 spectra can be used alone for the database search or, more commonly, the characteristic doublet ions from the asymmetrically cleaved cross-linker are selected for MS3 fragmentation of each peptide separately during acquisition. These MS3 spectra are then used for database searching along with the deduced masses of the parent peptides.

References

- 546 1. Leitner, A., Faini, M., Stengel, F. & Aebersold, R. Crosslinking and Mass
547 Spectrometry: An Integrated Technology to Understand the Structure and Function
548 of Molecular Machines. *Trends Biochem. Sci.* **41**, 20–32 (2016).
- 549 2. Pham, N. D., Parker, R. B. & Kohler, J. J. Photocrosslinking approaches to
550 interactome mapping. *Curr. Opin. Chem. Biol.* **17**, 90–101 (2013).
- 551 3. Yu, C. & Huang, L. Cross-Linking Mass Spectrometry: An Emerging Technology for
552 Interactomics and Structural Biology. *Anal. Chem.* **90**, 144–165 (2018).
- 553 4. Schweppe, D. K. *et al.* Mitochondrial protein interactome elucidated by chemical
554 cross-linking mass spectrometry. *Proc. Natl. Acad. Sci. U. S. A.* (2017).
555 doi:10.1073/pnas.1617220114
- 556 5. Chavez, J. D. *et al.* Quantitative interactome analysis reveals a chemoresistant
557 edgotype. *Nat. Commun.* **6**, 7928 (2015).
- 558 6. Liu, F., Rijkers, D. T. S., Post, H. & Heck, A. J. R. Proteome-wide profiling of protein
559 assemblies by cross-linking mass spectrometry. *Nat. Methods* **12**, 1179–1184
560 (2015).
- 561 7. Belsom, A., Schneider, M., Fischer, L., Brock, O. & Rappsilber, J. Serum Albumin
562 Domain Structures in Human Blood Serum by Mass Spectrometry and
563 Computational Biology. *Mol. Cell. Proteomics* **15**, 1105–1116 (2016).
- 564 8. Greber, B. J. *et al.* Ribosome. The complete structure of the 55S mammalian
565 mitochondrial ribosome. *Science* **348**, 303–308 (2015).
- 566 9. Plaschka, C. *et al.* Architecture of the RNA polymerase II-Mediator core initiation
567 complex. *Nature* **518**, 376–380 (2015).
- 568 10. Bui, K. H. *et al.* Integrated structural analysis of the human nuclear pore complex
569 scaffold. *Cell* **155**, 1233–1243 (2013).
- 570 11. Kosinski, J. *et al.* Molecular architecture of the inner ring scaffold of the human
571 nuclear pore complex. *Science* **352**, 363–365 (2016).
- 572 12. Kim, S. J. *et al.* Integrative structure and functional anatomy of a nuclear pore
573 complex. *Nature* (2018). doi:10.1038/nature26003
- 574 13. Chen, Z. A. *et al.* Architecture of the RNA polymerase II–TFIIF complex revealed by
575 cross-linking and mass spectrometry. *EMBO J.* **29**, 717–726 (2010).
- 576 14. Herzog, F. *et al.* Structural probing of a protein phosphatase 2A network by
577 chemical cross-linking and mass spectrometry. *Science* **337**, 1348–1352 (2012).
- 578 15. Joachimiak, L. A., Walzthoeni, T., Liu, C. W., Aebersold, R. & Frydman, J. The
579 structural basis of substrate recognition by the eukaryotic chaperonin TRiC/CCT.
580 *Cell* **159**, 1042–1055 (2014).
- 581 16. Kalisman, N., Adams, C. M. & Levitt, M. Subunit order of eukaryotic TRiC/CCT
582 chaperonin by cross-linking, mass spectrometry, and combinatorial homology
583 modeling. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 2884–2889 (2012).
- 584 17. Leitner, A. *et al.* The molecular architecture of the eukaryotic chaperonin TRiC/CCT.
585 *Structure* **20**, 814–825 (2012).

- 586 18. Lasker, K. *et al.* Molecular architecture of the 26S proteasome holocomplex
587 determined by an integrative approach. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 1380–
588 1387 (2012).
- 589 19. Erzberger, J. P. *et al.* Molecular architecture of the 40S-eIF1-eIF3 translation
590 initiation complex. *Cell* **158**, 1123–1135 (2014).
- 591 20. Nguyen, V. Q. *et al.* Molecular architecture of the ATP-dependent chromatin-
592 remodeling complex SWR1. *Cell* **154**, 1220–1231 (2013).
- 593 21. Tosi, A. *et al.* Structure and subunit topology of the INO80 chromatin remodeler and
594 its nucleosome complex. *Cell* **154**, 1207–1219 (2013).
- 595 22. Martinez-Rucobo, F. W. *et al.* Molecular Basis of Transcription-Coupled Pre-mRNA
596 Capping. *Mol. Cell* **58**, 1079–1089 (2015).
- 597 23. Yan, C. *et al.* Structure of a yeast spliceosome at 3.6-angstrom resolution. *Science*
598 **349**, 1182–1191 (2015).
- 599 24. Ferber, M. *et al.* Automated structure modeling of large protein assemblies using
600 crosslinks as distance restraints. *Nat. Methods* **13**, 515–520 (2016).
- 601 25. Karaca, E., Rodrigues, J. P. G. L. M., Graziadei, A., Bonvin, A. M. J. J. &
602 Carlomagno, T. M3: an integrative framework for structure determination of
603 molecular machines. *Nat. Methods* **14**, 897–902 (2017).
- 604 26. Politis, A. *et al.* A mass spectrometry-based hybrid method for structural modeling of
605 protein complexes. *Nat. Methods* **11**, 403–406 (2014).
- 606 27. Konermann, L., Pan, J. & Liu, Y.-H. Hydrogen exchange mass spectrometry for
607 studying protein structure and dynamics. *Chem. Soc. Rev.* **40**, 1224–1234 (2011).
- 608 28. Han, Y., Luo, J., Ranish, J. & Hahn, S. Architecture of the *Saccharomyces*
609 *cerevisiae* SAGA transcription coactivator complex. *EMBO J.* **33**, 2534–2546
610 (2014).
- 611 29. Algret, R. *et al.* Molecular architecture and function of the SEA complex, a
612 modulator of the TORC1 pathway. *Mol. Cell. Proteomics* **13**, 2855–2870 (2014).
- 613 30. Maiolica, A. *et al.* Structural analysis of multiprotein complexes by cross-linking,
614 mass spectrometry, and database searching. *Mol. Cell. Proteomics* **6**, 2200–2211
615 (2007).
- 616 31. Merkley, E. D. *et al.* Mixed-Isotope Labeling with LC-IMS-MS for Characterization of
617 Protein-Protein Interactions by Chemical Cross-Linking. *J. Am. Soc. Mass*
618 *Spectrom.* **24**, 444–449 (2013).
- 619 32. Pettelkau, J. *et al.* Structural analysis of guanylyl cyclase-activating protein-2
620 (GCAP-2) homodimer by stable isotope-labeling, chemical cross-linking, and mass
621 spectrometry. *J. Am. Soc. Mass Spectrom.* **24**, 1969–1979 (2013).
- 622 33. Arlt, C., Ihling, C. H. & Sinz, A. Structure of full-length p53 tumor suppressor probed
623 by chemical cross-linking and mass spectrometry. *Proteomics* **15**, 2746–2755
624 (2015).
- 625 34. Barysz, H. *et al.* Three-dimensional topology of the SMC2/SMC4 subcomplex from
626 chicken condensin I revealed by cross-linking and molecular modelling. *Open Biol.*
627 **5**, 150005 (2015).

- 628 35. Belsom, A., Schneider, M., Brock, O. & Rappsilber, J. Blind Evaluation of Hybrid
629 Protein Structure Analysis Methods based on Cross-Linking. *Trends Biochem. Sci.*
630 **41**, 564–567 (2016).
- 631 36. Schneider, M., Belsom, A. & Rappsilber, J. Protein Tertiary Structure by
632 Crosslinking/Mass Spectrometry. *Trends Biochem. Sci.* **43**, 157–169 (2018).
- 633 37. Young, M. M. *et al.* High throughput protein fold identification by using experimental
634 constraints derived from intramolecular cross-links and mass spectrometry. *Proc.*
635 *Natl. Acad. Sci. U. S. A.* **97**, 5802–5806 (2000).
- 636 38. Singh, P., Nakatani, E., Goodlett, D. R. & Catalano, C. E. A pseudo-atomic model
637 for the capsid shell of bacteriophage lambda using chemical cross-linking/mass
638 spectrometry and molecular modeling. *J. Mol. Biol.* **425**, 3378–3388 (2013).
- 639 39. Dos Santos, R. N. *et al.* Enhancing protein fold determination by exploring the
640 complementary information of chemical cross-linking and coevolutionary signals.
641 *Bioinformatics* (2018). doi:10.1093/bioinformatics/bty074
- 642 40. Schneider, M., Belsom, A., Rappsilber, J. & Brock, O. Blind testing of cross-
643 linking/mass spectrometry hybrid methods in CASP11. *Proteins* **84 Suppl 1**, 152–
644 163 (2016).
- 645 41. Belsom, A. *et al.* Blind testing cross-linking/mass spectrometry under the auspices
646 of the 11th critical assessment of methods of protein structure prediction (CASP11).
647 *Wellcome Open Res* **1**, 24 (2016).
- 648 42. Ding, Y.-H. *et al.* Modeling Protein Excited-state Structures from ‘Over-length’
649 Chemical Cross-links. *J. Biol. Chem.* **292**, 1187–1196 (2017).
- 650 43. Komolov, K. E. *et al.* Structural and Functional Analysis of a β 2-Adrenergic
651 Receptor Complex with GRK5. *Cell* **169**, 407–421.e16 (2017).
- 652 44. Chen, Z. A. & Rappsilber, J. Protein dynamics in solution by quantitative cross-
653 linking/mass spectrometry. *Trends Biochem. Sci.* **IN PRESS**, (2018).
- 654 45. Fischer, L., Chen, Z. A. & Rappsilber, J. Quantitative cross-linking/mass
655 spectrometry using isotope-labelled cross-linkers. *J. Proteomics* **88**, 120–128
656 (2013).
- 657 46. Chen, Z. A. *et al.* Structure of Complement C3(H₂O) Revealed By Quantitative
658 Cross-Linking/Mass Spectrometry And Modeling. *Mol. Cell. Proteomics* **15**, 2730–
659 2743 (2016).
- 660 47. Schmidt, C. *et al.* Comparative cross-linking and mass spectrometry of an intact F-
661 type ATPase suggest a role for phosphorylation. *Nat. Commun.* **4**, 1985 (2013).
- 662 48. Walzthoeni, T. *et al.* xTract: software for characterizing conformational changes of
663 protein complexes by quantitative cross-linking mass spectrometry. *Nat. Methods*
664 **12**, 1185–1190 (2015).
- 665 49. Chen, Z. A., Fischer, L., Cox, J. & Rappsilber, J. Quantitative Cross-linking/Mass
666 Spectrometry Using Isotope-labeled Cross-linkers and MaxQuant. *Mol. Cell.*
667 *Proteomics* **15**, 2769–2778 (2016).
- 668 50. Tomko, R. J., Jr *et al.* A Single α Helix Drives Extensive Remodeling of the
669 Proteasome Lid and Completion of Regulatory Particle Assembly. *Cell* **163**, 432–

- 670 444 (2015).
- 671 51. Yu, C. *et al.* Gln40 deamidation blocks structural reconfiguration and activation of
672 SCF ubiquitin ligase complex by Nedd8. *Nat. Commun.* **6**, 10053 (2015).
- 673 52. Boelt, S. G. *et al.* Mapping the Ca(2+) induced structural change in calreticulin. *J.*
674 *Proteomics* **142**, 138–148 (2016).
- 675 53. Beilsten-Edmands, V. *et al.* eIF2 interactions with initiator tRNA and eIF2B are
676 regulated by post-translational modifications and conformational dynamics. *Cell*
677 *Discov* **1**, 15020 (2015).
- 678 54. Koehler, C. *et al.* Genetic code expansion for multiprotein complex engineering. *Nat.*
679 *Methods* **13**, 997–1000 (2016).
- 680 55. Chen, Z. *et al.* Quantitative cross-linking/mass spectrometry reveals subtle protein
681 conformational changes. *Wellcome Open Res* **1**, 5 (2016).
- 682 56. Gavin, A.-C. *et al.* Proteome survey reveals modularity of the yeast cell machinery.
683 *Nature* **440**, 631–636 (2006).
- 684 57. Krogan, N. J. *et al.* Global landscape of protein complexes in the yeast
685 *Saccharomyces cerevisiae*. *Nature* **440**, 637–643 (2006).
- 686 58. Havugimana, P. C. *et al.* A census of human soluble protein complexes. *Cell* **150**,
687 1068–1081 (2012).
- 688 59. Kristensen, A. R., Gsponer, J. & Foster, L. J. A high-throughput approach for
689 measuring temporal changes in the interactome. *Nat. Methods* **9**, 907–909 (2012).
- 690 60. Makowski, M. M., Willems, E., Jansen, P. W. T. C. & Vermeulen, M. Cross-linking
691 immunoprecipitation-MS (xIP-MS): Topological Analysis of Chromatin-associated
692 Protein Complexes Using Single Affinity Purification. *Mol. Cell. Proteomics* **15**, 854–
693 865 (2016).
- 694 61. Shi, Y. *et al.* A strategy for dissecting the architectures of native macromolecular
695 assemblies. *Nat. Methods* **12**, 1135–1138 (2015).
- 696 62. Häupl, B., Ihling, C. H. & Sinz, A. Protein Interaction Network of Human Protein
697 Kinase D2 Revealed by Chemical Cross-Linking/Mass Spectrometry. *J. Proteome*
698 *Res.* **15**, 3686–3699 (2016).
- 699 63. Wang, X. *et al.* Molecular Details Underlying Dynamic Structures and Regulation of
700 the Human 26S Proteasome. *Mol. Cell. Proteomics* **16**, 840–854 (2017).
- 701 64. Tan, D. *et al.* Trifunctional cross-linker for mapping protein-protein interaction
702 networks and comparing protein conformational states. *Elife* **5**, (2016).
- 703 65. Yang, B. *et al.* Identification of cross-linked peptides from complex samples. *Nat.*
704 *Methods* **9**, 904–906 (2012).
- 705 66. Liu, F., Lössl, P., Scheltema, R., Viner, R. & Heck, A. J. R. Optimized fragmentation
706 schemes and data analysis strategies for proteome-wide cross-link identification.
707 *Nat. Commun.* **8**, 15473 (2017).
- 708 67. Kastritis, P. L. *et al.* Capturing protein communities by structural proteomics in a
709 thermophilic eukaryote. *Mol. Syst. Biol.* **13**, 936 (2017).
- 710 68. Kaake, R. M. *et al.* A New in Vivo Cross-linking Mass Spectrometry Platform to
711 Define Protein–Protein Interactions in Living Cells. *Mol. Cell. Proteomics* **13**, 3533–

- 712 3543 (2014).
- 713 69. Chavez, J. D., Weisbrod, C. R., Zheng, C., Eng, J. K. & Bruce, J. E. Protein
714 interactions, post-translational modifications and topologies in human cells. *Mol.*
715 *Cell. Proteomics* **12**, 1451–1467 (2013).
- 716 70. Wu, X. *et al.* In vivo protein interaction network analysis reveals porin-localized
717 antibiotic inactivation in *Acinetobacter baumannii* strain AB5075. *Nat. Commun.* **7**,
718 13414 (2016).
- 719 71. Liu, F., Lössl, P., Rabbitts, B. M., Balaban, R. S. & Heck, A. J. R. The interactome of
720 intact mitochondria by cross-linking mass spectrometry provides evidence for
721 coexisting respiratory supercomplexes. *Mol. Cell. Proteomics* **17**, 216–232 (2018).
- 722 72. Chavez, J. D., Schweppe, D. K., Eng, J. K. & Bruce, J. E. In Vivo Conformational
723 Dynamics of Hsp90 and Its Interactors. *Cell Chem Biol* **23**, 716–726 (2016).
- 724 73. Schweppe, D. K. *et al.* Host-Microbe Protein Interactions during Bacterial Infection.
725 *Chem. Biol.* **22**, 1521–1530 (2015).
- 726 74. Tran, B. Q., Goodlett, D. R. & Goo, Y. A. Advances in protein complex analysis by
727 chemical cross-linking coupled with mass spectrometry (CXMS) and bioinformatics.
728 *Biochim. Biophys. Acta* **1864**, 123–129 (2016).
- 729 75. Fischer, L. & Rappsilber, J. On the Quirks of Error Estimation in Cross-Linking/
730 Mass Spectrometry. *Anal. Chem.* (2017). doi:10.1021/acs.analchem.6b03745
- 731 76. Walzthoeni, T. *et al.* False discovery rate estimation for cross-linked peptides
732 identified by mass spectrometry. *Nat. Methods* **9**, 901–903 (2012).
- 733 77. Suchanek, M., Radzikowska, A. & Thiele, C. Photo-leucine and photo-methionine
734 allow identification of protein-protein interactions in living cells. *Nat. Methods* **2**,
735 261–267 (2005).
- 736 78. Götze, M. *et al.* StavroX—A Software for Analyzing Crosslinked Products in Protein
737 Interaction Studies. *J. Am. Soc. Mass Spectrom.* **23**, 76–87 (2012).
- 738 79. Du, X. *et al.* Xlink-identifier: an automated data analysis platform for confident
739 identifications of chemically cross-linked peptides using tandem mass spectrometry.
740 *J. Proteome Res.* **10**, 923–931 (2011).
- 741 80. Panchaud, A., Singh, P., Shaffer, S. A. & Goodlett, D. R. xComb: a cross-linked
742 peptide database approach to protein-protein interaction analysis. *J. Proteome Res.*
743 **9**, 2508–2515 (2010).
- 744 81. Singh, P. *et al.* Characterization of protein cross-links via mass spectrometry and an
745 open-modification search strategy. *Anal. Chem.* **80**, 8799–8806 (2008).
- 746 82. Giese, S. H., Fischer, L. & Rappsilber, J. A Study into the Collision-induced
747 Dissociation (CID) Behavior of Cross-Linked Peptides. *Mol. Cell. Proteomics* **15**,
748 1094–1104 (2016).
- 749 83. Ji, C., Li, S., Reilly, J. P., Radivojac, P. & Tang, H. XLSearch: a Probabilistic
750 Database Search Algorithm for Identifying Cross-Linked Peptides. *J. Proteome Res.*
751 **15**, 1830–1841 (2016).
- 752 84. Trnka, M. J., Baker, P. R., Robinson, P. J. J., Burlingame, A. L. & Chalkley, R. J.
753 Matching cross-linked peptide spectra: only as good as the worse identification. *Mol.*


- 754 *Cell. Proteomics* **13**, 420–434 (2014).
- 755 85. Yu, F., Li, N. & Yu, W. Exhaustively Identifying Cross-Linked Peptides with a Linear
756 Computational Complexity. *J. Proteome Res.* **16**, 3942–3952 (2017).
- 757 86. Hoopmann, M. R. *et al.* Kojak: efficient analysis of chemically cross-linked protein
758 complexes. *J. Proteome Res.* **14**, 2190–2198 (2015).
- 759 87. Yuan, Z. *et al.* Structural basis of Mcm2-7 replicative helicase loading by ORC-Cdc6
760 and Cdt1. *Nat. Struct. Mol. Biol.* **24**, 316–324 (2017).
- 761 88. Petrotchenko, E. V., Olkhovik, V. K. & Borchers, C. H. Isotopically coded cleavable
762 cross-linker for studying protein-protein interaction and protein complexes. *Mol. Cell.*
763 *Proteomics* **4**, 1167–1179 (2005).
- 764 89. Zelter, A. *et al.* Isotope signatures allow identification of chemically cross-linked
765 peptides by mass spectrometry: a novel method to determine interresidue distances
766 in protein structures through cross-linking. *J. Proteome Res.* **9**, 3583–3589 (2010).
- 767 90. Ihling, C. *et al.* Isotope-labeled cross-linkers and Fourier transform ion cyclotron
768 resonance mass spectrometry for structural analysis of a protein/peptide complex.
769 *J. Am. Soc. Mass Spectrom.* **17**, 1100–1113 (2006).
- 770 91. Holding, A. N., Lamers, M. H., Stephens, E. & Skehel, J. M. Hekate: software suite
771 for the mass spectrometric analysis and three-dimensional visualization of cross-
772 linked protein samples. *J. Proteome Res.* **12**, 5923–5933 (2013).
- 773 92. Rinner, O. *et al.* Identification of cross-linked peptides from large sequence
774 databases. *Nat. Methods* **5**, 315–318 (2008).
- 775 93. Leitner, A., Walzthoeni, T. & Aebersold, R. Lysine-specific chemical cross-linking of
776 protein complexes and identification of cross-linking sites using LC-MS/MS and the
777 xQuest/xProphet software pipeline. *Nat. Protoc.* **9**, 120–137 (2013).
- 778 94. Kao, A. *et al.* Development of a novel cross-linking strategy for fast and accurate
779 identification of cross-linked peptides of protein complexes. *Mol. Cell. Proteomics*
780 **10**, (2011).
- 781 95. Soderblom, E. J. & Goshe, M. B. Collision-induced dissociative chemical cross-
782 linking reagents and methodology: Applications to protein structural characterization
783 using tandem mass spectrometry analysis. *Anal. Chem.* **78**, 8059–8068 (2006).
- 784 96. Buncherd, H., Roseboom, W., de Koning, L. J., de Koster, C. G. & de Jong, L. A gas
785 phase cleavage reaction of cross-linked peptides for protein complex topology
786 studies by peptide fragment fingerprinting from large sequence database. *J.*
787 *Proteomics* **108**, 65–77 (2014).
- 788 97. Müller, M. Q., Dreiocker, F., Ihling, C. H., Schäfer, M. & Sinz, A. Cleavable cross-
789 linker for protein structure analysis: reliable identification of cross-linking products by
790 tandem MS. *Anal. Chem.* **82**, 6958–6968 (2010).
- 791 98. Yu, C., Kandur, W., Kao, A., Rychnovsky, S. & Huang, L. Developing new isotope-
792 coded mass spectrometry-cleavable cross-linkers for elucidating protein structures.
793 *Anal. Chem.* **86**, 2099–2106 (2014).
- 794 99. Dreiocker, F., Müller, M. Q., Sinz, A. & Schäfer, M. Collision-induced dissociative
795 chemical cross-linking reagent for protein structure characterization: applied Edman

- 796 chemistry in the gas phase. *J. Mass Spectrom.* **45**, 178–189 (2010).
- 797 100. Petrotchenko, E. V., Serpa, J. J. & Borchers, C. H. An isotopically coded CID-
798 cleavable biotinylated cross-linker for structural proteomics. *Mol. Cell. Proteomics*
799 **10**, (2011).
- 800 101. Hage, C., Falvo, F., Schäfer, M. & Sinz, A. Novel Concepts of MS-Cleavable Cross-
801 linkers for Improved Peptide Structure Analysis. *J. Am. Soc. Mass Spectrom.*
802 (2017).
- 803 102. Hage, C., Iacobucci, C., Rehkamp, A., Arlt, C. & Sinz, A. The First Zero-Length
804 Mass Spectrometry-Cleavable Cross-Linker for Protein Structure Analysis. *Angew.*
805 *Chem. Int. Ed Engl.* (2017).
- 806 103. Clifford-Nunn, B., Showalter, H. D. H. & Andrews, P. C. Quaternary diamines as
807 mass spectrometry cleavable crosslinkers for protein interactions. *J. Am. Soc. Mass*
808 *Spectrom.* **23**, 201–212 (2012).
- 809 104. Chakrabarty, J. K., Naik, A. G., Fessler, M. B., Munske, G. R. & Chowdhury, S. M.
810 Differential Tandem Mass Spectrometry-Based Cross-Linker: A New Approach for
811 High Confidence in Identifying Protein Cross-Linking. *Anal. Chem.* **88**, 10215–10222
812 (2016).
- 813 105. Tang, X. & Bruce, J. E. A new cross-linking strategy: protein interaction reporter
814 (PIR) technology for protein–protein interaction studies. *Mol. Biosyst.* **6**, 939–947
815 (2010).
- 816 106. Petrotchenko, E. V. & Borchers, C. H. ICC-CLASS: isotopically-coded cleavable
817 crosslinking analysis software suite. *BMC Bioinformatics* **11**, 64 (2010).
- 818 107. Götze, M. *et al.* Automated assignment of MS/MS cleavable cross-links in protein
819 3D-structure analysis. *J. Am. Soc. Mass Spectrom.* **26**, 83–97 (2015).
- 820 108. Hoopmann, M. R., Weisbrod, C. R. & Bruce, J. E. Improved strategies for rapid
821 identification of chemically cross-linked peptides using protein interaction reporter
822 technology. *J. Proteome Res.* **9**, 6323–6333 (2010).
- 823 109. Anderson, G. A., Tolic, N., Tang, X., Zheng, C. & Bruce, J. E. Informatics strategies
824 for large-scale novel cross-linking analysis. *J. Proteome Res.* **6**, 3412–3421 (2007).
- 825 110. Vizcaíno, J. A. *et al.* The mzIdentML Data Standard Version 1.2, Supporting
826 Advances in Proteome Informatics. *Mol. Cell. Proteomics* **16**, 1275–1285 (2017).
- 827 111. Combe, C. W., Fischer, L. & Rappsilber, J. xiNET: cross-link network maps with
828 residue resolution. *Mol. Cell. Proteomics* **14**, 1137–1147 (2015).
- 829 112. Grimm, M., Zimniak, T., Kahraman, A. & Herzog, F. xVis: a web server for the
830 schematic visualization and interpretation of crosslink-derived spatial restraints.
831 *Nucleic Acids Res.* **43**, W362–9 (2015).
- 832 113. Kosinski, J. *et al.* Xlink Analyzer: software for analysis and visualization of cross-
833 linking data in the context of three-dimensional structures. *J. Struct. Biol.* **189**, 177–
834 183 (2015).
- 835 114. Zheng, C. *et al.* XLink-DB: Database and Software Tools for Storing and Visualizing
836 Protein Interaction Topology Data. *J. Proteome Res.* **12**, 1989–1995 (2013).
- 837 115. Kahraman, A., Malmström, L. & Aebersold, R. Xwalk: computing and visualizing


838 distances in cross-linking experiments. *Bioinformatics* **27**, 2163–2164 (2011).
839 116. Courcelles, M. *et al.* CLMSVault: A Software Suite for Protein Cross-Linking Mass-
840 Spectrometry Data Analysis and Visualization. *J. Proteome Res.* (2017).
841 117. Riffle, M., Jaschob, D., Zelter, A. & Davis, T. N. ProXL (Protein Cross-Linking
842 Database): A Platform for Analysis, Visualization, and Sharing of Protein Cross-
843 Linking Mass Spectrometry Data. *J. Proteome Res.* **15**, 2863–2870 (2016).
844 118. Kolbowski, L., Combe, C. & Rappsilber, J. xiSPEC: web-based visualization,
845 analysis and sharing of proteomics data. *Nucleic Acids Res.* (2018).

846


a Select cross-linker




b Reaction




c Digestion




f Database search




e Mass spectrometry acquisition




d Enrichment






a Annotated Spectra




b Network and residue level views of cross-linked proteins




c 3D structure visualisation and benchmarking


3D structure view



Circle view





Distogram





— Satisfied link (<25 Å Ca-Ca distance)
— Long-distance link

a Universal approach



b Labelled cross-linker approach



c MS-cleavable cross-linker approach

